US EditionNovo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients - Novo Nordisk (NYSE:NVO)
Amycretin showed dose-dependent HbA1c reductions up to 1.8% and weight loss up to 14.5% in type 2 diabetes patients, prompting Novo Nordisk's phase 3 trial plans for 2026.
6 Articles
6 Articles
Amycretin reduces weight, HbA1c in phase 2 trial of patients with diabetes
Amycretin, a novel GLP-1 and amylin receptor agonist, reduced weight and HbA1c in a phase 2 trial of patients with type 2 diabetes, according to topline results announced by Novo Nordisk.The trial is the first of the drug, which is being developed as a once-weekly subcutaneous agent and a once-daily oral agent, in patients with type 2 diabetes, the company stated in a press release. As Healio
Novo Nordisk’s next-generation diabetes injection reduced patients’ blood sugar levels and helped them lose weight in a study that may be a positive sign for the future portfolio of troubled pharmaceutical products. When given as a weekly injection, the compound called amicretin helped people lose up to 14.5 percent of their body weight for 36 weeks. Those who took it as oral medicine once a day lost up to 10.1 percent of their weight, Novo repo…
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients - Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes. The update marks the first evaluation of amycretin in people with type 2 diabetes. Novo Nordisk is planning to initiate a phase 3 development program with amycretin for adults with type 2 diabetes in 2026. In June, the company said it planned to initiate a phase 3 development for amycretin for adults with overweight or obesit…
Pharmalittle: We’re reading about a Novo next-gen diabetes drug, a Novartis gene therapy, and more
Hello there and happy Tuesday from STAT’s London outpost, with Andrew Joseph here filling in for Mr. Pharmalot for the day. While it feels like things are slowing down stateside ahead of the Thanksgiving holiday, this place is busy diving full speed into Christmas already. We just hope you can enjoy whatever you’re celebrating whenever and wherever that may be. Now to some headlines. … A next-generation treatment from Novo Nordisk helped patient…
Amycretin: Weight Loss & HbA1c Benefits in Trial
Archyde The Dawn of Dual-Action Diabetes & Weight Loss Drugs: What Amycretin’s Phase 2 Results Mean for the Future A potential game-changer in the fight against type 2 diabetes and obesity… You can read the full story here: Amycretin: Weight Loss & HbA1c Benefits in Trial.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
